Dose-Finding Based on Efficacy-Toxicity Trade-Offs

Cites Work

Dose-Finding Designs for HIV Studies
Title not available (Why is that?)
Spherical-Radial Integration Rules for Bayesian Computation
Title not available (Why is that?)
Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials
A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
Approaches for Optimal Sequential Decision Analysis in Clinical Trials
A Simplex Method for Function Minimization
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer

Cited In (66)

Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials
A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies
A conversation with Nancy Flournoy
Bayesian models and decision algorithms for complex early phase clinical trials
Information in a two-stage adaptive optimal design
Some geometric methods for constructing decision criteria based on two-dimensional parame\-ters
Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages
TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes
Optimizing the concentration and bolus of a drug delivered by continuous infusion
A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint
TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
Optimal drug dosage subject to constraints
Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
DROID: dose-ranging approach to optimizing dose in oncology drug development
Title not available (Why is that?)
Sequential Methods in Multi-Arm Clinical Trials
Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
A bargaining approach for resolving the tradeoff between beneficial and harmful drug responses
Coherence principles in dose-finding studies
Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs
gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials
A seamless phase II/III design with dose optimization for oncology drug development
A new characterization of Elfving's method for high dimensional computation
Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials
A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials
A semiparametric Bayesian approach to population finding with time‐to‐event and toxicity data in a randomized clinical trial
A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials
Title not available (Why is that?)
Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
Bayesian phase I/II adaptively randomized oncology trials with combined drugs
A Bayesian Phase I/II Trial Design for Immunotherapy
A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
Correlated endpoints: simulation, modeling, and extreme correlations
Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
Efficiency of bridging between related dose finding studies
Rejoinder
A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
escalation
Adaptive designs for selecting drug combinations based on efficacy-toxicity response
Simple benchmark for complex dose finding studies
Optimal design to discriminate between rival copula models for a bivariate binary response
A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity
trialr
A multi-armed Bayesian ordinal outcome utility-based sequential trial with a pairwise null clustering prior
Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
A review of phase 2-3 clinical trial designs
A Bayesian design for phase I cancer therapeutic vaccine trials
REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
Change-point joint model for identification of plateau of activity in early phase trials
A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications
Combined criteria for dose optimisation in early phase clinical trials
Comparative review of novel model-assisted designs for phase I/II clinical trials
A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death
Hybrid design evaluating new biomarkers when there is an existing screening test
A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials
Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials
Seamless phase I/II design for novel anticancer agents with competing disease progression
Subgroup-specific dose finding for phase I-II trials using Bayesian clustering
Utility based approach in individualized optimal dose selection using machine learning methods
Group sequential designs for clinical trials with bivariate endpoints

   Recommendations

Optimal dose‐finding for efficacy–safety models 👍 👎
Adaptive designs for dose-finding based on efficacy-toxicity response 👍 👎
Optimal designs for dose-finding experiments in toxicity studies 👍 👎
Title not available (Why is that?) 👍 👎
Target toxicity design for phase I dose-finding 👍 👎
Performance Measures in Dose‐Finding Experiments 👍 👎

This page was built for publication: Dose-Finding Based on Efficacy-Toxicity Trade-Offs

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q70261)